618070-65-8

Usage

Uses

Used in Medicinal Chemistry:
Ethyl 5-amino-1-(2-fluorophenyl)-1H-pyrazole-4-carboxylate is used as a building block or intermediate in the synthesis of various bioactive compounds for medicinal chemistry research. Its unique structural features, including the fluorophenyl group, may contribute to the development of new drugs with improved pharmacological properties.
Used in Pharmaceutical Research:
Ethyl 5-amino-1-(2-fluorophenyl)-1H-pyrazole-4-carboxylate is used as a potential candidate for drug discovery in pharmaceutical research. Its structural elements, such as the pyrazole core and the fluorine atom, may provide opportunities for the design and optimization of novel therapeutic agents with enhanced efficacy and selectivity.

Upstream product

• 68350-76-5 2-cyano-3-methoxyacrylic acid ethyl ester 
• 2368-80-1 2-fluorophenylhydrazine 
• 94-05-3 ethyl (ethoxymethylene)cyanoacetate 
• 348-54-9 2-Fluoroaniline 

Downstream Products

• 618091-61-5 5-amino-1-(2-fluorophenyl)-1H-pyrazole-4-carboxylic acid 

Relevant academic research and scientific papers

Deciphering the robustness of pyrazolo-pyridine carboxylate core structure-based compounds for inhibiting α-synuclein in transgenic C. elegans model of Synucleinopathy

Parkinson's disease (PD), a calamitous neurodegenerative disorder with no cure till date, is closely allied with the misfolding and aggregation of α-Synuclein (α -Syn). Inhibition of α-Syn aggregation is one of the optimistic approaches for the treatment for PD. Here, we carried out hypothesis-driven studies towards synthesising a series of pyrazolo-pyridine carboxylate containing compounds (7a–7m) targeted at reducing deleterious α-Syn aggregation. The target compounds were synthesized through multi-step organic synthesis reactions. From docking studies, compounds 7b, 7g and 7i displayed better interaction with the key residues of α-Syn with values: ?6.8, ?8.9 and ?7.2 Kcal/mol, respectively. In vivo transgenic C. elegans model of Synucleinopathy was used to evaluate the ability of the designed and synthesized compounds to inhibit α-Syn aggregation. These lead compounds 7b, 7g and 7i displayed 1.7, 2.4 and 1.5-fold inhibition of α-Syn with respect to the control. Further, the strategy of employing pyrazolo-pyridine-based compounds worked with success and these scaffolds could be further modified and validated for betterment of endpoints associated with PD.

5-Amino-pyrazoles as potent and selective p38α inhibitors

The synthesis and structure-activity relationships (SAR) of p38α MAP kinase inhibitors based on a 5-amino-pyrazole scaffold are described. These studies led to the identification of compound 2j as a potent and selective inhibitor of p38α MAP kinase with excellent cellular potency toward the inhibition of TNFα production. Compound 2j was highly efficacious in vivo in inhibiting TNFα production in an acute murine model of TNFα production. X-ray co-crystallography of a 5-amino-pyrazole analog 2f bound to unphosphorylated p38α is also disclosed.